Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 25, 2023

SELL
$191.51 - $216.16 $191 - $216
-1 Reduced 9.09%
10 $2,000
Q2 2023

Aug 10, 2023

BUY
$187.64 - $206.25 $1,688 - $1,856
9 Added 450.0%
11 $2,000
Q1 2023

May 15, 2023

SELL
$127.59 - $203.08 $182,326 - $290,201
-1,429 Reduced 99.86%
2 $0
Q4 2022

Jan 30, 2023

BUY
$117.37 - $139.17 $24,060 - $28,529
205 Added 16.72%
1,431 $0
Q3 2022

Nov 15, 2022

SELL
$135.27 - $180.11 $135 - $180
-1 Reduced 0.08%
1,226 $168,000
Q2 2022

Aug 09, 2022

SELL
$108.81 - $179.33 $196,946 - $324,587
-1,810 Reduced 59.6%
1,227 $217,000
Q1 2022

May 09, 2022

SELL
$119.61 - $157.85 $270,677 - $357,214
-2,263 Reduced 42.7%
3,037 $437,000
Q4 2021

Feb 07, 2022

BUY
$142.57 - $190.86 $89,106 - $119,287
625 Added 13.37%
5,300 $819,000
Q3 2021

Nov 09, 2021

BUY
$142.45 - $169.82 $89,743 - $106,986
630 Added 15.57%
4,675 $794,000
Q2 2021

Aug 13, 2021

BUY
$135.08 - $161.1 $131,567 - $156,911
974 Added 31.72%
4,045 $638,000
Q1 2021

May 13, 2021

BUY
$137.51 - $190.8 $415,005 - $575,834
3,018 Added 5694.34%
3,071 $426,000
Q4 2020

Feb 02, 2021

BUY
$164.63 - $211.93 $8,725 - $11,232
53 New
53 $9,000

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.